JC
BPMC

JBF Capital’s Blueprint Medicines BPMC Stock Holding History

JBF Capital’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-22,322
Closed -$1.74M – 92
2018
Q3 		$1.74M Hold
22,322
– – 0.26% 22
2018
Q2 		$1.42M Buy
22,322
+11,500
+106% +$915K 0.21% 32
2018
Q1 		$992K Buy
+10,822
New +$933K 0.16% 37

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

JBF Capital's BPMC Position: Q4 2018 in Review

JBF Capital sold out of Blueprint Medicines (BPMC) in Q4 2018, closing a stake of 22,322 shares — an estimated $1.74M sold.

JBF Capital first reported a position in BPMC in Q1 2018 and held it in 3 quarters. The position peaked at $1.74M in Q3 2018. 162 funds tracked by Wall St. Rank hold BPMC as of Q4 2018.

  • JBF Capital reported no remaining Blueprint Medicines position as of Q4 2018 after selling out during the quarter.
  • JBF Capital sold 22,322 Blueprint Medicines shares in Q4 2018, an estimated $1.74M.
  • JBF Capital first reported a position in Blueprint Medicines in Q1 2018 and held it in 3 quarters.
  • JBF Capital's Blueprint Medicines position peaked at $1.74M in Q3 2018.
  • 162 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2018.

Based on JBF Capital's 13F filing for Q4 2018, filed 12 Feb 2019.